Skip to main content

Table 2 Univariate and multivariate analysis of the prognostic value of miR-25 and miR-142 in PFS

From: Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Variables Number of patients Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Age 380 1.015 (1.002–1.027) 0.024 1.012 (0.999–1.025) 0.062
Stage    < 0.001   < 0.001
 Early 51 1   1  
 Late 329 6.894 (3.400–13.981) 5.861 (2.873–11.954)
Grade    0.384   /
 Low 74 1   /  
 High 281 0.871 (0.639–1.188)   /  
 NA 25 /   /  
Debulking    0.002   < 0.001
 Optimal 290 1   1  
 Suboptimal 88 2.115 (1.594–2.807)   1.712 (1.278–2.292)  
 Inoperable 2 /    
Treatment    0.009   0.003
 Standard 181 1   1  
 Standard+Bevacizumab 199 0.711 (0.550–0.918)   0.676 (0.521–0.876)  
miR-25 expression    0.006   0.020
 Low 341 1   1  
 High 39 0.501 (0.306–0.822)   0.554 (0.338–0.910)  
miR-142 expression    0.747   /
 Low 99 1   /  
 High 281 1.050 (0.782–1.410)   /